These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1269 related items for PubMed ID: 25813457

  • 1. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M, Munda B, Svab V, Locatelli I.
    J Affect Disord; 2015 Jun 01; 178():149-59. PubMed ID: 25813457
    [Abstract] [Full Text] [Related]

  • 2. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.
    Curr Med Res Opin; 2014 Aug 01; 30(8):1673-85. PubMed ID: 24627974
    [Abstract] [Full Text] [Related]

  • 3. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
    Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A.
    Lancet Psychiatry; 2018 Sep 01; 5(9):727-738. PubMed ID: 30097390
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis.
    Hanwella R, Senanayake M, de Silva V.
    BMC Psychiatry; 2011 Nov 10; 11():176. PubMed ID: 22074258
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in the Treatment of Attention-Deficit Hyperactivity Disorder in Adults: A Systematic Review and Meta-analysis.
    Stuhec M, Lukić P, Locatelli I.
    Ann Pharmacother; 2019 Feb 10; 53(2):121-133. PubMed ID: 30117329
    [Abstract] [Full Text] [Related]

  • 10. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P, Häge A, Coghill DR, Caballero B, Adeyi B, Anderson CS, Sikirica V, Cardo E.
    Eur Child Adolesc Psychiatry; 2016 Feb 10; 25(2):141-9. PubMed ID: 25999292
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
    Pozzi M, Carnovale C, Mazhar F, Peeters GGAM, Gentili M, Nobile M, Radice S, Clementi E.
    J Clin Psychopharmacol; 2019 Feb 10; 39(4):386-392. PubMed ID: 31205193
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta-analysis and meta-regression.
    Cunill R, Castells X, Tobias A, Capellà D.
    Pharmacoepidemiol Drug Saf; 2013 Sep 10; 22(9):961-9. PubMed ID: 23813665
    [Abstract] [Full Text] [Related]

  • 15. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.
    Health Technol Assess; 2006 Jul 10; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
    [Abstract] [Full Text] [Related]

  • 16. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
    Cortese S, Adamo N, Mohr-Jensen C, Hayes AJ, Bhatti S, Carucci S, Del Giovane C, Atkinson LZ, Banaschewski T, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A, Coghill D, European ADHD Guidelines Group (EAGG).
    BMJ Open; 2017 Jan 10; 7(1):e013967. PubMed ID: 28073796
    [Abstract] [Full Text] [Related]

  • 17. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
    Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, Hsieh SC, Bai Z, Hossain A, Skidmore B, Tsakonas E, Chojecki D, Mamdani M, Wells GA.
    PLoS One; 2020 Jan 10; 15(10):e0240584. PubMed ID: 33085721
    [Abstract] [Full Text] [Related]

  • 18. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
    Rodrigues R, Lai MC, Beswick A, Gorman DA, Anagnostou E, Szatmari P, Anderson KK, Ameis SH.
    J Child Psychol Psychiatry; 2021 Jun 10; 62(6):680-700. PubMed ID: 32845025
    [Abstract] [Full Text] [Related]

  • 19. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 10; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of a head-to-head study of lisdexamfetamine dimesylate and atomoxetine: evaluation of Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomised, double-blind, Phase IIIb study. CNS Drugs 2013;27:1081-1092. doi: 10.1007/s40263-013-0104-8 ClinicalTrials.gov: NCT01106430.
    Banaschewski T, Rothermel B, Poustka L.
    Expert Opin Pharmacother; 2014 Sep 10; 15(13):1961-5. PubMed ID: 25085429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.